Summary
In clinical trials, the clinical endpoint is often replaced by an intermediate endpoint, known in some instances as a “surrogate” endpoint. The reasons for the substitution are often both practical and financial. At present, no theoretical basis or practical guidelines exist to help in the choice of surrogate endpoints.
An approach is proposed here, based on three provisos which can be verified using one of a series of equations, if sufficient data on the pathophysiology and epidemiology of the disease are available. It is shown that even a strong statistical correlation is not a sufficient criterion for the definition of a surrogate endpoint.
It is apparent that results obtained with the commonly used “surrogate” endpoints should be cautiously considered and that the assessment of treatments should, when possible, be based on clinical rather than intermediate endpoints.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Friedman L, Furberg CD, DeMets DL (1984) Fundamentals of clinical trials, 2nd edn. PSG Publishing, Littleton
Moleur P, Boissel JP (1987) Definition of a surrogate endpoint. Controlled Clinical Trials 8: 304
Herson J (1989) The use of surrogate endpoints in clinical trials (an introduction to a series of four papers). Stat Med 8: 403–404
Ellenberg SS, Hamilton JM (1989) Surrogate endpoints in clinical trials: cancer. Stat Med 8: 405–413
Wittes J, Lakatos L, Probstfield J (1989) Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8: 415–425
Hillis A, Seigel D (1989) Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat Med 8: 427–430
Ruskin JN (1989) Editorial: the Cardiac Arrhythmia Suppression Trial. New Engl J Med 321: 386–388
Winkle RA (1980) Detection of patients at high risk for sudden death: the role of electrocardiographic monitoring. In: Kulbertus HE, Wellens HJJ (eds) Sudden death. Martinus Nijhof, The Hague
The CAST investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 321: 406–412
Kannel WB, Gordon T, Schwartz MJ (1971) Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 27: 335–346
Pooling Project Research Group (1978) Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chron Dis 31: 201–306
MacMahon S, Petro R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke, and coronary heart disease. Part 1. prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765–774
Boissel JP, Gueyffier F (1990) High blood pressure and clinical events linked with atherosclerosis. In: Atkinson J, Capdeville C, Zannad F (eds) Coronary and cerebrovascular effects of antihypertensive drugs. Transmedico Europe Ltd, UK, p 240–252
Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke, and coronary heart disease. Part 2. short term reductions in blood pressure: overview of randomized drug trials in epidemiological context. Lancet 335: 827–838
Okamoto K, Yamori Y, Nagaoka A (1974) Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 34: 1143–1153
Lievre M, Leizorovicz A, Boissel JP (1991) Critères intermé diaires et critères de substitution dans le développement des antiarytbmiques. Arch Mal Coeur 84: 27–33
Hine LK, Laird NM, Hewitt P, Chalmers TC (1989) Meta analysis of empirical antiarrhythmic therapy after myocardial infarction. J Am Med Assoc 262: 3037–3040
Slater W, Lampert S, Podrid J, Lown B (1988) Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 61: 349–353
Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431–440
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boissel, J.P., Collet, J.P., Moleur, P. et al. Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol 43, 235–244 (1992). https://doi.org/10.1007/BF02333016
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02333016